Medsenic

Quick facts

Phase 2 pipeline

• Arsenic Trioxide Injectable Solution · Oncology
  Arsenic trioxide induces differentiation and apoptosis in leukemic cells, particularly in acute promyelocytic leukemia (APL), through multiple pathways including PML-RARA protein degradation and reactive oxygen species generation.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Medsenic portfolio CI brief
• Medsenic pipeline updates RSS